Bryan D. Smith

2.3k citations

52 papers · 961 indexed · h-index 16

Gastroenterology top 10%
- Gastrointestinal Tumor Research and Treatment 5
Genetics top 10%
- Chronic Lymphocytic Leukemia Research 5
Hematology top 10%
- Chronic Myeloid Leukemia Treatments 6
Oncology
Biochemistry top 10%
Pulmonary and Respiratory Medicine
- Sarcoma Diagnosis and Treatment 6
Molecular Biology
- Biochemical and Molecular Research 5
- DNA and Nucleic Acid Chemistry 4
- Ubiquitin and proteasome pathways 4
Rheumatology
- Musculoskeletal synovial abnormalities and treatments 4

Co-authors: D. Scott Bohle Ronald T. Raines Daniel L. Flynn Scott Paulson Bernhard Hansert Chen‐Hsiung Hung Scott Wise Matthew B. Soellner
Cited by: Gastroenterology Genetics Hematology
Journals: Cancer Research (15 papers)Molecular Cancer Therapeutics (6 papers)Bioorganic & Medicinal Chemistry Letters (4 papers)
Partner nations: United States Canada Palestinian Territory

In The Last Decade

Bryan D. Smith

49 papers receiving 934 citations

Peers

Countries citing papers authored by Bryan D. Smith

Since Specialization

Citations

This map shows the geographic impact of Bryan D. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan D. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan D. Smith more than expected).

Fields of papers citing papers by Bryan D. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan D. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan D. Smith. The network helps show where Bryan D. Smith may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Bryan D. Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bryan D. Smith Line = papers co-authored together Bryan D. Smith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer eLife ·Phaedra C. Ghazi,Пентина Юлия Сергеевна,Frankie N. Cassell,Charles W. Lyman,Mark R. Silvis,Yun Zhang,何育林,Bryan D. Smith,Guillermina Lozano,Daniel L. Flynn,Eric L. Snyder,Conan G. Kinsey,Martin McMahon	2024	5
2	29 (PB017): A novel small molecule activator of the integrated stress response kinase GCN2 shows potent preclinical antitumor activity as monotherapy and in combination with standard of care agents European Journal of Cancer ·Gada Al-Ani,LPasquini,Mikael Morelius,Pui-tak Ho,Jennifer Zwicker,Shamama Javed,Molly M. Hood,Dashyant Dhanak,Darren Flynn,Bryan D. Smith	2024	0
3	Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer eLife ·Phaedra C. Ghazi,Пентина Юлия Сергеевна,Frankie N. Cassell,Charles W. Lyman,Mark R. Silvis,Yun Zhang,何育林,Bryan D. Smith,Guillermina Lozano,Daniel L. Flynn,Eric L. Snyder,Conan G. Kinsey,Martin McMahon	2024	9
4	The MOTION Study: A Randomized, Phase III Study of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor Future Oncology ·William D. Tap,Jia-Shan Lin,Enst Morten Hevrøy,Bryan D. Smith,Matthew L. Sherman,Rodrigo Ruiz‐Soto,Michiel A. J. van de Sande,R. Lor Randall,Nicholas M. Bernthal,Hans Gelderblom	2023	6
5	Abstract 1377: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with encorafenib and cetuximab in BRAF V600E mutant colorectal cancer models Cancer Research ·何育林,Manfred Keuchler,貞介吉田,Bryan D. Smith,Daniel L. Flynn	2023	2
6	Abstract 4938: DP-9024, an investigational small molecule modulator of the integrated stress response kinase GCN2, synergizes with asparaginase therapy in leukemic tumors Cancer Research ·Gada Al-Ani,И.П. Маркова,LPasquini,Pui-tak Ho,MA Flores Manzur,Zhujun Mayu,Yu Mi Ahn,Stacie L. Bulfer,F. Dutry,Molly M. Hood,Khushi Shaileshbhai,Shen Guangjun,Arantza López Lorenzana,Beverly Besmanos,Bertrand Le Bourdonnec,Bryan D. Smith,Daniel L. Flynn	2023	0
7	Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT) Bioorganic & Medicinal Chemistry Letters ·Timothy M. Caldwell,Yu Mi Ahn,Stacie L. Bulfer,Cynthia B. Leary,Molly M. Hood,Wei-Ping Lu,Lakshminarayana Vogeti,Subha Vogeti,Michael D. Kaufman,Scott Wise,Bertrand Le Bourdonnec,Bryan D. Smith,Daniel L. Flynn	2022	19
8	Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Timothy M. Caldwell,Michael D. Kaufman,Scott Wise,Yu Mi Ahn,Molly M. Hood,Wei-Ping Lu,William C. Patt,Thiwanka B. Samarakoon,Lakshminarayana Vogeti,Subha Vogeti,Marceli Talita Pereira,Stacie L. Bulfer,Bertrand Le Bourdonnec,Bryan D. Smith,Daniel L. Flynn	2022	7
9	Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis Molecular Cancer Therapeutics ·Anu Gupta,Jarnail Singh,Shiraishi,César Serrano,Daniel L. Flynn,Bryan D. Smith	2021	20
10	Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages Molecular Cancer Therapeutics ·Bryan D. Smith,Michael D. Kaufman,Scott Wise,Yu Mi Ahn,Timothy M. Caldwell,Cynthia B. Leary,Wei-Ping Lu,Jeffrey C Webster,Lakshminarayana Vogeti,Subha Vogeti,Breelyn A. Wilky,Lara E. Davis,Jia-Shan Lin,Rodrigo Ruiz‐Soto,Daniel L. Flynn	2021	40
11	The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors Molecular Cancer Therapeutics ·Allison S. Harney,George S. Karagiannis,Jeanine Pignatelli,Bryan D. Smith,Ece Kadioglu,Scott Wise,Molly M. Hood,Michael D. Kaufman,Cynthia B. Leary,S. Gherib,Gada Al-Ani,Xiaohong Chen,David Entenberg,Maja H. Oktay,Yarong Wang,Lawrence Chun,Michele De Palma,Joan G. Jones,Daniel L. Flynn,John S. Condeelis	2017	105
12	Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST) Annals of Oncology ·Filip Jankú,A.R. Abdul Razak,Michael S. Gordon,Darren Flynn,Michael D. Kaufman,Michelle Roberts,Bryan D. Smith,Neeta Somaiah,P. M. Patel,Samer Salah,Pedro Pinheiro de,David J. Greensmith,Yara María Alonso-Triana,O. Rosen,Suzanne George	2017	6
13	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia Haematologica ·Jörge E. Cortes,Moshe Talpaz,Hedy Smith,David S. Snyder,Jean Khoury,Kapil N. Bhalla,Javier Pinilla‐Ibarz,Richard A. Larson,David Mitchell,Scott Wise,Thomas J. Rutkoski,Bryan D. Smith,Daniel L. Flynn,Hagop M. Kantarjian,Oliver Rosen,Richard A. Van Etten	2016	31
14	Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models Neuro-Oncology ·Yuji Piao,Soon Young Park,Verlene Henry,Bryan D. Smith,Ningyi Tiao,Daniel L. Flynn,John de Groot	2016	52
15	The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile Cancer Research ·Christopher A. Eide,Lauren T. Adrian,Jeffrey Tyner,Gennadii Sherbina,David J. Anderson,Scott Wise,Bryan D. Smith,Peter A. Petillo,Daniel L. Flynn,Michael W. Deininger,Thomas O’Hare,Brian Druker	2011	77
16	Site-specific folate conjugation to a cytotoxic protein Bioorganic & Medicinal Chemistry Letters ·Bryan D. Smith,Marcos Boissiere Tremaria,Ronald T. Raines	2011	10
17	Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region Bioorganic & Medicinal Chemistry Letters ·Yu Mi Ahn,Michael Clare,Carol L. Ensinger,Molly M. Hood,John Lord,Wei-Ping Lu,David F. Miller,William C. Patt,Bryan D. Smith,Lakshminarayana Vogeti,Michael D. Kaufman,Peter A. Petillo,Scott Wise,Jan Abendroth,Lawrence Chun,Robin Clark,M.D. Feese,Hidong Kim,Lance Stewart,Daniel L. Flynn	2010	26
18	Functional and structural analyses of N‐acylsulfonamide‐linked dinucleoside inhibitors of RNase A FEBS Journal ·Nethaji Thiyagarajan,Bryan D. Smith,Ronald T. Raines,K. Ravi Acharya	2010	12
19	Activation switch pocket inhibitors target the T315I mutant of BCR-ABL Cancer Research ·Thomas O’Hare,Christopher A. Eide,Scott Wise,Bryan D. Smith,Peter A. Petillo,Daniel L. Flynn,Brian Druker	2008	1
20	Activase Region on Chloroplast Ribulose-1,5-bisphosphate Carboxylase/Oxygenase Journal of Biological Chemistry ·Christiane Ott,Bryan D. Smith,Archie R. Portis,Robert J. Spreitzer	2000	49

About Bryan D. Smith

Bryan D. Smith is a scholar working on Gastroenterology, Hematology, Genetics, Cancer Research and Molecular Biology, having authored 52 papers that have together received 961 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (6 papers), Sarcoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Biochemical and Molecular Research (5 papers), Gastrointestinal Tumor Research and Treatment (5 papers), Musculoskeletal synovial abnormalities and treatments (4 papers), DNA and Nucleic Acid Chemistry (4 papers) and Ubiquitin and proteasome pathways (4 papers). The work is most often cited by research in Gastroenterology (55 citations), Genetics (103 citations), Hematology (106 citations), Oncology (200 citations) and Biochemistry (43 citations). Bryan D. Smith has collaborated with scholars based in United States, Canada and Palestinian Territory. Frequent co-authors include D. Scott Bohle, Ronald T. Raines, Daniel L. Flynn, Scott Paulson, Bernhard Hansert, Chen‐Hsiung Hung, Scott Wise, Matthew B. Soellner, Michael D. Kaufman and Molly M. Hood. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Bioorganic & Medicinal Chemistry Letters, European Journal of Cancer and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact